We used decision analysis to model 3 empiric therapies for the treatment of patients seen initially in an outpatient setting. The model was based on a population of patients with cellulitis who ...
(NYSE/TSX:BHC), today announced that PrCABTREOTM (clindamycin phosphate ... today announced that it has filed a patent infringement lawsuit ... LAVAL, QC / ACCESSWIRE / June 14, 2024 / Bausch ...
This isn’t quite right. One of the numbers does not relate to a patent at all, while three are patents for cures or research relating to the different diseases. Three are patents for pathogens, but ...